Telephone
61.3.9660.4900
Address
Level 11 535 Bourke Street Melbourne, Victoria (VIC) 3000
Description
Clinuvel Pharmaceuticals Ltd. operates as a biopharmaceutical company. The firm engages in the development of SCENESSE, its proprietary photoprotective drug. It also offers drugs for the treatment of various skin disorders. The company was founded by Robert Thomas Dorr on December 14, 1999 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 13.97 - 28.72
Trade Value (12mth)
AU$383,536.00
1 week
-7.26%
1 month
8.28%
YTD
-22.14%
1 year
-17.13%
All time high
45.88
EPS 3 yr Growth
102.700%
EBITDA Margin
53.20%
Operating Cashflow
$37m
Free Cash Flow Return
25.30%
ROIC
21.00%
Interest Coverage
N/A
Quick Ratio
7.10
Shares on Issue (Fully Dilluted)
52m
HALO Sector
Healthcare
Next Company Report Date
28-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
4.23
Date | Announcements |
---|---|
31 October 23 |
Chair's Address
×
Chair's Address |
31 October 23 |
CEO Presentation AGM
×
CEO Presentation AGM |
31 October 23 |
Results of Meeting
×
Results of Meeting |
31 October 23 |
CLINUVEL Appoints New Chair
×
CLINUVEL Appoints New Chair |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 October 22 |
Quarterly Activities/Appendix 4C Cash Flow Report Re-issued
×
Quarterly Activities/Appendix 4C Cash Flow Report Re-issued |
31 March 22 |
CLINUVEL Newsletter II - March 2022
×
CLINUVEL Newsletter II - March 2022 |
31 January 23 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 January 22 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
31 August 22 |
CLINUVEL Investor Webinar Financial Results 2022
×
CLINUVEL Investor Webinar Financial Results 2022 |
30 March 23 |
Investor Presentation - NYC Nasdaq Event
×
Investor Presentation - NYC Nasdaq Event |
30 March 22 |
First XP-V Patient Treated in Third CUV DNA Repair Study
×
First XP-V Patient Treated in Third CUV DNA Repair Study |
30 March 10 |
Clinuvel Corporate Presentation
×
Clinuvel Corporate Presentation |
30 June 23 |
Two Grounds of Appeal Upheld by NICE Panel
×
Two Grounds of Appeal Upheld by NICE Panel |
30 June 23 |
Notification regarding unquoted securities - CUV
×
Notification regarding unquoted securities - CUV |
30 August 23 |
CLINUVEL Investor Webinar Transcript
×
CLINUVEL Investor Webinar Transcript |
30 August 22 |
Appendix 4E and Annual Report 2022
×
Appendix 4E and Annual Report 2022 |
30 August 22 |
Dividend/Distribution - CUV
×
Dividend/Distribution - CUV |
30 August 22 |
Revenue Growth Drives CLINUVEL's Full Year Profit
×
Revenue Growth Drives CLINUVEL's Full Year Profit |
30 August 22 |
Appendix 4G and Corporate Governance Statement
×
Appendix 4G and Corporate Governance Statement |
29 September 23 |
Notice of Annual General Meeting/Proxy Form
×
Notice of Annual General Meeting/Proxy Form |
29 September 23 |
Board Changes after AGM
×
Board Changes after AGM |
29 September 06 |
2006 Annual Report
×
2006 Annual Report |
29 June 23 |
Presentation - Melbourne Twilight Briefing
×
Presentation - Melbourne Twilight Briefing |
29 June 23 |
Notification of cessation of securities - CUV
×
Notification of cessation of securities - CUV |
29 August 23 |
Appendix 4E and Annual Report to Shareholders 2023
×
Appendix 4E and Annual Report to Shareholders 2023 |
29 August 23 |
Dividend/Distribution - CUV
×
Dividend/Distribution - CUV |
29 August 23 |
CLINUVEL delivering increases in annual revenue, profit
×
CLINUVEL delivering increases in annual revenue, profit |
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Historical data
Forecasted data
Load More
Load Less
Upload your portfolio and gain access to 3-year dividend forecasts for each holding with HALO Global. Empower your decision-making and maximize returns with our advanced analytical tool. Try it today.
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.